Tumor Biology

, Volume 33, Issue 5, pp 1727–1732 | Cite as

Acquired xanthine dehydrogenase expression shortens survival in patients with resected adenocarcinoma of lung

  • Hayato Konno
  • Yoshihiro Minamiya
  • Hajime Saito
  • Kazuhiro Imai
  • Yasushi Kawaharada
  • Satoru Motoyama
  • Jun-ichi Ogawa
Research Article


Xanthine dehydrogenase (XDH), also known as xanthine oxidoreductase (XOR), has long been recognized as the key enzyme in the catabolism of purines, oxidizing hypoxanthine into xanthine and then xanthine into uric acid. In addition, levels of XDH expression are reportedly related to the prognosis of patients with malignant tumors, though the relationship between the clinicopathological features of lung cancer and XDH is not fully understood. We therefore used semiquantitative real-time reverse transcription polymerase chain reaction to assess expression of XDH mRNA in tumor samples from 88 patients with adenocarcinoma of the lung. We then correlated XDH mRNA levels with known clinicopathological factors. We found that the 5-year overall survival rate among patients strongly expressing XDH was significantly poorer than among those expressing lower levels of XDH (P < 0.001; log-rank test). Normal lung tissue does not express XDH. Multivariate Cox proportional hazard analyses revealed that being male (hazard ratio, 3.14; 95 % confidence interval (CI), 1.45–7.07; P = 0.004), nodal metastasis positivity (hazard ratio, 5.74; 95 % CI, 1.94–19.3; P = 0.001), and high XDH expression (hazard ratio, 2.33; 95 % CI, 1.11–5.02; P = 0.026) were all independent factors affecting 5-year disease-free survival. In conclusion, high tumoral XDH expression is an independent predictor of a poor prognosis in patients with adenocarcinoma of the lung.


Adenocarcinoma Lung cancer Prognosis Xanthine dehydrogenase Xanthine oxidase 


Conflicts of interest



  1. 1.
    Boueiz A, Damarla M, Hassoun PM. Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am J Physiol Lung Cell Mol Physiol. 2008;294:L830–40.CrossRefPubMedGoogle Scholar
  2. 2.
    McCord JM. Oxygen-derived radicals: a link between reperfusion injury and inflammation. Fed Proc. 1987;46(7):2402–6.PubMedGoogle Scholar
  3. 3.
    Parks DA, Granger DN. Xanthine oxidase: biochemistry and physiology. Acta Physiol Scand Suppl. 1986;548:87–99.PubMedGoogle Scholar
  4. 4.
    Ashraf M, Samra ZQ. Subcellular distribution of xanthine oxidase during cardiac ischemia and reperfusion: an immunocytochemical study. J Submicrosc Cytol Pathol. 1993;25:193–201.PubMedGoogle Scholar
  5. 5.
    Yokoyama Y, Beckman JS, Beckman TK, Wheat JK, Cash TG, Freeman BA, Parks DA. Circulating xanthine oxidase: potential mediator of ischemic injury. Am J Physiol. 1990;258:G564–G70.PubMedGoogle Scholar
  6. 6.
    Samra ZQ, Siddique Z. Distribution of xanthine oxidase during calcium paradox conditions of rat heart. Punjab Univ J Zool. 1998;13:89–98.Google Scholar
  7. 7.
    Halliwell B, Gutteridge JM, Cross CE. Free radicals, antioxidants, and human disease: where are we now? J Lab Clin Med. 1992;119:598–620.PubMedGoogle Scholar
  8. 8.
    Samra ZQ, Pervaiz S, Shaheen S, Dar N, Athar MA. Determination of oxygen derived free radicals producer (xanthine oxidase) and scavenger (paraoxonase1) enzymes and lipid parameters in different cancer patients. Clin Lab. 2011;57:741–7.PubMedGoogle Scholar
  9. 9.
    Nishikawa M. Reactive oxygen species in tumor metastasis. Cancer Lett. 2008;266:53–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med. 2002;32:1102–15.CrossRefPubMedGoogle Scholar
  11. 11.
    Klaunig JE, Kamendulis LM. The role of oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–67.CrossRefPubMedGoogle Scholar
  12. 12.
    Wright RM, McManaman JL, Repine JE. Alcohol-induced breast cancer: a proposed mechanism. Free Radic Biol Med. 1999;26:348–54.CrossRefPubMedGoogle Scholar
  13. 13.
    Castro GD, Delgado de Layño AM, Costantini MH, Castro JA. Cytosolic xanthine oxidoreductase mediated bioactivation of ethanol to acetaldehyde and free radicals in rat breast tissue. Its potential role in alcohol-promoted mammary cancer. Toxicology. 2001;160:11–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Kaynar H, Meral M, Turhan H, Keles M, Celik G, Akcay F. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett. 2005;227:133–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsao SM, Yin MC, Liu WH. Oxidant stress and B vitamins status in patients with non-small cell lung cancer. Nutr Cancer. 2007;59:8–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Linder N, Rapola J, Raivio KO. Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Investig. 1999;79:967–74.PubMedGoogle Scholar
  17. 17.
    Linder N, Lundin J, Isola J, Lundin M, Raivio KO, Joensuu H. Down-regulated xanthine oxidoreductase is a feature of aggressive breast cancer. Clin Cancer Res. 2005;11:4372–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Linder N, Martelin E, Lundin M, Louhimo J, Nordling S, Haglund C, Lundin J. Xanthine oxidoreductase—clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. Eur J Cancer. 2009;45:648–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Linder N, Haglund C, Lundin M, Nordling S, Ristimäki A, Kokkola A, Mrena J, Wiksten JP, Lundin J. Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol. 2006;59:965–71.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kim AW, Batus M, Myint R, Fidler MJ, Basu S, Bonomi P, Faber LP, Wightman SC, Warren WH, McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay MJ. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011;71:186–90.CrossRefPubMedGoogle Scholar
  21. 21.
    Sobin L, Wittekind CH, editors. TNM classification of malignant tumours. 6th ed. New York: Wiley; 2002. p. 99–103.Google Scholar
  22. 22.
    Oesterreich S. Scaffold attachment factors SAFB1 and SAFB2: innocent bystanders or critical players in breast tumorigenesis? J Cell Biochem. 2003;90:653–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Lin J, Xu P, LaVallee P, Hoidal JR. Identification of proteins binding to E-Box/Ku86 sites and function of the tumor suppressor SAFB1 in transcriptional regulation of the human xanthine oxidoreductase gene. J Biol Chem. 2008;283:29681–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Taibi G, Carruba G, Cocciadiferro L, Granata OM, Nicotra CM. Low levels of both xanthine dehydrogenase and cellular retinol binding protein are responsible for retinoic acid deficiency in malignant human mammary epithelial cells. Ann N Y Acad Sci. 2009;1155:268–72.CrossRefPubMedGoogle Scholar
  25. 25.
    Tsukioka T, Nishiyama N, Iwata T, Nagano K, Tei K, Suehiro S. Preoperative serum oxidative stress marker as a strong indicator of nodal involvement in clinical stage I lung adenocarcinoma. Int J Clin Oncol. 2011. doi: 10.1007/s10147-011-0283-6
  26. 26.
    Mongaret C, Alexandre J, Thomas-Schoemann A, Bermudez E, Chéreau C, Nicco C, Goldwasser F, Weill B, Batteux F, Lemare F. Tumor invasion induced by oxidative stress is dependent on membrane ADAM 9 protein and its secreted form. Int J Cancer. 2011;129:791–8.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Hayato Konno
    • 1
  • Yoshihiro Minamiya
    • 1
  • Hajime Saito
    • 1
  • Kazuhiro Imai
    • 1
  • Yasushi Kawaharada
    • 1
  • Satoru Motoyama
    • 1
  • Jun-ichi Ogawa
    • 1
  1. 1.Division of Chest Surgery, Akita University HospitalAkita University Graduate School of MedicineAkita CityJapan

Personalised recommendations